Creative Biolabs Launches Membrane Protein Antibody Discovery Service

SHIRLEY, NY - Nov 20, 2017 - Growing interest is focusing on the potential of membrane protein as a breaking point of antibody-based therapy and diagnosis for various diseases. However, there are many drawbacks in the expression of membrane protein which serves as the antigen, including misfolding, low expression level, difficult extraction, heterogeneous production, incomplete modification and conformational change. These drawbacks result in low efficiency of corresponding antibody production and hinder the progress of research project. 

Many researchers know that research methods and professional practices of membrane protein antibodies are constantly changing. Only by acquiring the latest techniques, can we achieve success in this field.

With experience in custom membrane protein antibody research, Creative Biolabs provides world-leading production service of antibody targeting membrane protein. It has developed MemProArt™ platform to meet the increasing needs from customers. The principle is to directly express and present target antigen of native conformation on the cell membrane, proteoliposome or lipoparticles.

Obtaining immunoreactivity from membrane protein with native conformation, this platform has perfectly conquered the shortcomings of traditional methods and has been proven to be of high efficiency in generating hundreds of antibodies. 

MemProArt™ platform has developed Phage Display Library Screening and hybridoma technique for monoclonal antibody screening and production respectively.

Phage Display Library Screening

A large library of phage-displayed human antibodies is incubated with mammalian cells presenting target membrane protein for antigen-antibody interaction. Phages with inert and low-affinity antibody can be washed away, while phages with high-affinity antibody are selected and propagated. Creative Biolabs has featured technique to greatly increase the affinity during panning procedure, and to select the most effective phage clone for amplification and subsequent application. 

Mouse/Rat Hybridoma Production

Creative Biolabs is able to stably over-express target membrane proteins on the surface of commercially available cell lines, such as HEK293, CHOK1, NIH3T3 and Sf9. The cells are then used to immunize mice/rats, followed by the isolation of splenic cells. Owing to their unique technique, Creative Biolabs could generate both rat and mouse hybridoma for rat and mouse monoclonal antibody production.

NativeTM Antibody Discovery Platform

Backed up by antigen-specific B lymphocytes cytometry technology, the Native™ Antibody Discovery Platform can screen single antigen-specific plasma cells to retrieve native antibodies with extremely superior in vivo properties. Antibody binders directly isolated from plasma cells not only ensures native-paired VH-VL, but also can benefit from in vivo selection and affinity maturation.

About Creative Biolabs

Creative Biolabs is a biotech company located in New York. Since the establishment in 2005, it has been providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early drug discovery and development.